← Back to headlines
Karyopharm Stock Plummets After Xpovio Fails Endometrial Cancer Trial
Karyopharm Therapeutics' stock fell sharply after its drug Xpovio did not meet its primary endpoint in a Phase 3 clinical trial for advanced endometrial cancer.
30 Jul, 23:38 — 30 Jul, 23:38
Sources
Showing 1 of 1 sources
Related Stories
Oldest Known Plague Outbreak Discovered in Siberia Dating Back 5,500 Years
just now
Rethymno: DEDDIE Official Arrested Over Fatal Fire, Cable Sparks Under Investigation
40m ago
Details Emerge in Lindsay Clancy Case as Officers Recount Finding Children
1h ago
Cristina Ulbrich, Wife of Falcons DC Jeff Ulbrich, Dies After Cancer Battle
1h ago